Tag: Monoclonal antibody

The global monoclonal antibody therapeutics market was valued at over $233 billion in 2023 and is projected to grow significantly [1.4.7]. For clinicians and patients wondering, *How can you recognize a monoclonal antibody drug?* The secret is systematically encoded in its generic name.

The global monoclonal antibody therapeutics market was valued at over USD 233 billion in 2024 and is projected to grow significantly [1.11.1]. This highlights the pivotal role of these engineered proteins in modern medicine. So, **what is an example of a monoclonal antibody being used?**

According to the FDA, Tepezza was the first medication approved to treat thyroid eye disease (TED), making its unique composition highly significant for patients. For those seeking to understand exactly **what are the ingredients in Tepezza infusion**, this guide explains its primary active component and the other inactive ingredients that form the final solution.

Developed by the Swiss pharmaceutical company Novartis, the groundbreaking biologic Cosentyx, or **secukinumab**, was the first interleukin-17A (IL-17A) inhibitor to receive FDA approval, marking a significant advancement for treating autoimmune and inflammatory diseases. Its development was a long process involving extensive research into inflammatory pathways.

Tepezza contains the active ingredient teprotumumab-trbw, which is a biologic drug produced from living cells, not a traditional chemically synthesized medication. This medication represents a specialized, targeted approach to therapy, marking a significant departure from older treatments for Thyroid Eye Disease (TED), the condition it is approved to treat. So, what is Tepezza made of and how does its unique composition work?

While the detectable concentration of a **rituximab infusion stay in your system** for a limited time, its therapeutic effect of B-cell depletion can last for many months after the drug is no longer in the bloodstream. Understanding the half-life and B-cell recovery timeline is crucial for managing treatment expectations and monitoring long-term effects.

The FDA has issued multiple serious, or 'boxed', warnings for rituximab due to significant adverse event reports. The most important safety information includes risks of fatal infusion reactions, progressive multifocal leukoencephalopathy (PML), and hepatitis B virus (HBV) reactivation.

In clinical studies, rituximab treatment has been shown to cause a rapid and profound depletion of peripheral B-cells within 72 hours. This monoclonal antibody, therefore, is primarily known for its ability to deplete B-cells by targeting a specific protein on their surface.

Infusion-related reactions are a very common side effect of rituximab, with some studies showing up to 77% of patients experiencing a reaction during their first infusion. This article explores the question, 'What are the most common adverse effects of rituximab?'.

The biologic drug Rituxan® was first approved by the FDA in 1997, and its generic name is rituximab. This monoclonal antibody has become a cornerstone therapy for various cancers and autoimmune conditions, with several biosimilar versions now available to offer patients more affordable options.